Adjuvant chemoradiation for pancreatic cancer: What does the evidence tell us?
Article
Chuong, MD, Boggs, DH, Patel, KN et al. (2014). Adjuvant chemoradiation for pancreatic cancer: What does the evidence tell us?
. 5(3), 166-177. 10.3978/j.issn.2078-6891.2014.025
Chuong, MD, Boggs, DH, Patel, KN et al. (2014). Adjuvant chemoradiation for pancreatic cancer: What does the evidence tell us?
. 5(3), 166-177. 10.3978/j.issn.2078-6891.2014.025
The role of adjuvant chemoradiation (CRT) for pancreas cancer remains unclear. A handful of randomized trials conducted decades of ago ignited a debate that continues today about whether CRT improves survival after surgery. The many flaws in these trials are well described in the literature, which include the use of antiquated radiation delivery techniques and suboptimal doses. Recent prospective randomized data is lacking, and we eagerly await the results the ongoing Radiation Therapy Oncology Group (RTOG) 0848 trial that is evaluating the utility of high quality adjuvant CRT in resected pancreas cancer patients. Until the results of RTOG 0848 are available we should look to other studies from the modern era to guide adjuvant treatment recommendations. Here we review the current state of the art for adjuvant pancreas CRT with respect to patient selection, radiation techniques, radiation dose, and integration with novel systemic agents.
